Literature DB >> 7990522

[Immunity against tetanus in adults over the age of 49 years].

G Cilla1, J R Sáenz-Domínguez, M Montes, C Part, E Pérez-Trallero.   

Abstract

BACKGROUND: Despite the existence of an effective, cheap vaccine with few side effects, tetanus remains present in Spain with most of the cases being observed in subjects over the age of 49 years. The present seroepidemiologic study was performed to detect the degree of protection of this population.
METHODS: The presence of antitetanic antibodies were determined in 324 subjects over the age of 49 (range: 50-88 years, mean 65.5 +/- 9.8 years) in Guipúzcoa. A passive hemagglutination technique (Tetan test; Istituto Sieroterápico Milanese) was used to detect tetanic antitoxoid antibodies following validation of the technique with a neutralizing test of the toxin in white mouse.
RESULTS: Only 12.3% (40/324) of the subjects were considered as immune versus tetanus. The older subjects were the least protected: 7.7% (8/104) of those over 70 years of age versus 17.3% (17/98) of those from 50-59 years of age (chi 2 = 4.34, p = 0.037). The women were globally less protected: 5.4% versus 17% (33/194) males (chi 2 = 9.72; p = 0.002).
CONCLUSIONS: Most of the adult population over the age of 49 years in Guipúzcoa is not protected against tetanus. This is in contrast with the situation observed in the infant and adolescent population. Specific preventive measures directed at the adult and elderly population should be undertaken.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7990522

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  2 in total

1.  Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial.

Authors:  Ghassan Dbaibo; Nabil El-Ayoubi; Soha Ghanem; Farah Hajar; Veronique Bianco; Jacqueline M Miller; Narcisa Mesaros
Journal:  Drugs Aging       Date:  2013-05       Impact factor: 3.923

2.  The safety and efficacy of the tetanus vaccine intramuscularly versus subcutaneously in anticoagulated patients: a randomized clinical trial.

Authors:  Fernando I Lago-Deibe; Maria-Victoria Martín-Miguel; Carmen Velicia-Peñas; Isabel Rey Gómez-Serranillos; Manuela Fontanillo-Fontanillo
Journal:  BMC Fam Pract       Date:  2014-08-28       Impact factor: 2.497

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.